Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH

Condition(s) targeted: Essential Hypertension; Left Ventricular Hypertrophy

Phase: N/A

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
F. Sonntag, MD, Principal Investigator, Affiliation: Cardiologist, Henstedt-Ulzburg
Andrea Pahor, MD, Study Chair, Affiliation: MED Dep., AstraZeneca Germany

The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12. 5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i. e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..

Official title: Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy

Study design: Cohort, Prospective

Primary outcome: to estimate under naturalistic conditions the impact of the antihypertensive therapy with candesartan or candesartan/HCT on pre-post change from Visit 1 to Visit 2 of Sokolow-Lyon index, Cornell index and Left Ventricular Mass Index.

Secondary outcome:

to estimate the change of the systolic and diastolic blood pressure, separately by the (maximum) prescribed daily dose of candesartan or candesartan/ HCT

to gain further insight into the occurrence of unknown, unexpected and/or rarely occurring adverse events (AE) by estimating the incidence under naturalistic conditions.

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- essential hypertension

- left ventricular hypertrophy

- under candesartan treatment

Exclusion Criteria:

Starting date: January 2007
Ending date: October 2007
Last updated: February 5, 2008